Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours

AIM: Patients with cancer are at an increased risk for severe coronavirus disease of 2019. We previously reported initial findings from a single centre prospective study evaluating antibody response after BNT162b2 vaccine, showing that adequate antibody response was achieved after two doses, but not...

Descripción completa

Detalles Bibliográficos
Autores principales: Margalit, Ofer, Shacham-Shmueli, Einat, Itay, Amit, Berger, Raanan, Halperin, Sharon, Jurkowicz, Menucha, Levin, Einav G., Olmer, Liraz, Regev-Yochay, Gili, Lustig, Yaniv, Rahav, Galia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013177/
https://www.ncbi.nlm.nih.gov/pubmed/35439660
http://dx.doi.org/10.1016/j.ejca.2022.03.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013177/
https://www.ncbi.nlm.nih.gov/pubmed/35439660
http://dx.doi.org/10.1016/j.ejca.2022.03.013

Ejemplares similares